Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome.

Autor: Aalbers AM; Department of Hematology, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands., van Daele PLA; Department of Internal Medicine, Division of Allergy & Clinical Immunology, and Department of Immunology, Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands., Dalm VASH; Department of Internal Medicine, Division of Allergy & Clinical Immunology, and Department of Immunology, Erasmus MC University Medical Center Rotterdam Rotterdam the Netherlands., Valk PJM; Department of Hematology, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands., Raaijmakers MHGP; Department of Hematology, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands.
Jazyk: angličtina
Zdroj: HemaSphere [Hemasphere] 2024 Jul 30; Vol. 8 (8), pp. e129. Date of Electronic Publication: 2024 Jul 30 (Print Publication: 2024).
DOI: 10.1002/hem3.129
Abstrakt: Competing Interests: The authors declare no conflict of interest.
Databáze: MEDLINE
Externí odkaz: